Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women

被引:2
|
作者
Upson, Kristen [1 ]
Harmon, Quaker E. [2 ]
Heffron, Renee [3 ,4 ]
Hall, Janet E. [5 ]
Wise, Lauren A. [6 ]
Wegienka, Ganesa [7 ]
Tokar, Erik J. [8 ]
Baird, Donna D. [2 ]
机构
[1] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, 909 Wilson Rd,Room 601, E Lansing, MI 48824 USA
[2] NIEHS, Epidemiol Branch, Res Triangle Pk, NC 27709 USA
[3] Univ Washington, Dept Global Hlth, Seattle, WA USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[5] NIEHS, Clin Res Branch, Res Triangle Pk, NC USA
[6] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA
[7] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA
[8] NIEHS, Stem Cells Toxicol Grp, Natl Toxicol Program Lab, Div Natl Toxicol Program, Res Triangle Pk, NC USA
基金
美国国家卫生研究院;
关键词
HUMAN VAGINAL HISTOLOGY; BONE-MINERAL DENSITY; HORMONAL CONTRACEPTION; MOBILIZATION; PERIMENOPAUSAL; PREMENOPAUSAL; OSTEOPOROSIS; PREGNANCY; EFFICACY; THERAPY;
D O I
10.1289/EHP7017
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
BACKGROUND: Injectable contraceptive use is common, with 74 million users worldwide. Use of the injectable contraceptive depot medroxyprogesterone acetate (DMPA) is associated with bone mineral density loss. We hypothesize that increased bone resorption with DMPA use allows for mobilization of the toxic metal lead stored in bone to blood, presenting users with increased systemic exposure to lead. OBJECTIVE: The objective of our study was to investigate the association between current DMPA use and blood lead concentrations. METHODS: We conducted a cross-sectional analysis using enrollment data from the Study of Environment, Lifestyle & Fibroids (SELF), a cohort of 1,693 African-American women who were 23-35 years of age. Data on DMPA use were collected by computer-assisted telephone interview. Blood lead concentrations were measured in whole blood samples among 1,548 participants (91% of cohort). We estimated the adjusted percent difference in blood lead concentrations and 95% confidence intervals (CI) between current DMPA users and nonusers using multivariable linear regression. RESULTS: Geometric mean blood lead concentration was 0:69 lg=dL (95% CI: 0.67, 0.71). After adjustment, current DMPA users (7% of cohort) had blood lead concentrations that were 18% higher than those of nonusers (95% CI: 8%, 29%). Similar associations were observed with additional analyses to assess for potential bias from smoking, DMPA-induced amenorrhea, use of estrogen-containing contraceptives, having given birth in the prior year, and history of medical conditions or current medication use associated with bone loss. DISCUSSION: Our results indicate that current DMPA use is associated with increased blood lead concentrations. Further research, particularly in populations highly exposed to lead, is warranted to consider tradeoffs between the adverse effects of lead on human health and the importance of DMPA as a contraceptive option to prevent unintended pregnancy.
引用
收藏
页码:117004 / 1
页数:7
相关论文
共 50 条
  • [21] Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women
    Lizarelli, Patricia Margareth
    Martins, Wellington Paula
    Vielra, Carolina Sales
    Soares, Gustavo Mafaldo
    Franceschini, Silvio Antonio
    Ferriani, Rul Alberto
    Patta, Maristela Carbol
    CONTRACEPTION, 2009, 79 (01) : 35 - 40
  • [22] Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use
    Wetmore, C. M.
    Ichikawa, L.
    LaCroix, A. Z.
    Ott, S. M.
    Scholes, D.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) : 519 - 527
  • [23] Association between caffeine intake and bone mass among young women: potential effect modification by depot medroxyprogesterone acetate use
    C. M. Wetmore
    L. Ichikawa
    A. Z. LaCroix
    S. M. Ott
    D. Scholes
    Osteoporosis International, 2008, 19 : 519 - 527
  • [24] Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture
    Lanza, Lee L.
    McQuay, Lisa J.
    Rothman, Kenneth J.
    Bone, Henry G.
    Kaunitz, Andrew M.
    Harel, Zeev
    Ataher, Quazi
    Ross, Douglas
    Arena, Philip L.
    Wolter, Kevin D.
    OBSTETRICS AND GYNECOLOGY, 2013, 121 (03): : 593 - 600
  • [25] Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma
    Harmon, Quaker E.
    Patchel, Stacy A.
    Zhao, Shanshan
    Umbach, David M.
    Cooper, Tracy E.
    Baird, Donna D.
    OBSTETRICS AND GYNECOLOGY, 2022, 139 (05): : 797 - 807
  • [26] Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years
    Busen, NH
    Britt, RB
    Rianon, N
    JOURNAL OF ADOLESCENT HEALTH, 2003, 32 (04) : 257 - 259
  • [27] Bone Mineral Density, Fracture, and Vitamin D in Adolescents and Young Women Using Depot Medroxyprogesterone Acetate
    Pitts, Sarah A. B.
    Feldman, Henry A.
    Dorale, Amanda
    Gordon, Catherine M.
    JOURNAL OF PEDIATRIC AND ADOLESCENT GYNECOLOGY, 2012, 25 (01) : 23 - 26
  • [28] ADOLESCENT AND YOUNG ADULT SATISFACTION AND PREFERENCE FOR SUBCUTANEOUS DEPOT MEDROXYPROGESTERONE ACETATE
    Wernick, Hunter
    Wentzel, Evelyn
    Jackson, Kenneth
    Schmuhl, Kelsey
    Valenti, Olivia
    Bonny, Andrea
    Berlan, Elise
    JOURNAL OF ADOLESCENT HEALTH, 2022, 70 (04) : S53 - S54
  • [29] Effect of depot medroxyprogesterone acetate on bone mineral density in adolescent women
    Zhang Mei-hua
    Zhang Wei
    Zhang Ai-dong
    Yang Yan
    Gai Ling
    CHINESE MEDICAL JOURNAL, 2013, 126 (21) : 4043 - 4047
  • [30] Depot medroxyprogesterone acetate for contraception causes weight and fat gain in women
    Marie Lofthouse
    Nature Clinical Practice Endocrinology & Metabolism, 2005, 1 (2): : 69 - 69